Inhibition of NLRP3 enhances pro-apoptotic effects of FLT3 inhibition in AML
Abstract FLT3 mutations occur in approximately 25% of all acute myeloid leukemia (AML) patients. While several FLT3 inhibitors have received FDA approval, their use is currently limited to combination therapies with chemotherapy, as resistance occurs, and efficacy decreases when the inhibitors are u...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | Cell Communication and Signaling |
Online Access: | https://doi.org/10.1186/s12964-025-02046-w |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|